Effects of rosuvastatin on the, in vivo, kinetic of VLDL [very low density lipoprotein] apoB [apolipoprotein-B], IDL [intermediate density lipoproteins] apoB, LDL apoB and HDL [high density lipoprotein] apoA1 [apolipoprotein-A1], using stable isotopes, in type 2 diabetic patients
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Hypertriglyceridaemia; Lipid metabolism disorders
- Focus Pharmacodynamics
Most Recent Events
- 03 May 2008 New trial record.